早期血液转录组特征可预测院外心脏骤停患者预后
该研究为临床试验NCT00999583的辅助研究,纳入69例院外心脏骤停后昏迷幸存者,在入院时及复苏后1天、3天采集血样进行全基因组表达分析(Illumina HumanHT-12 V4 BeadChip,>34,000基因)。患者按60天脑功能分类(CPC)分为神经预后良好(CPC 1-2)与不良(CPC>2)两组。结果显示促红细胞生成素(EPO)未影响第0天和第1天的转录组反应;预后不良组与良好组在第0天有76个转录本存在差异,该特征持续至第1天,表现为适应性免疫下调伴固有免疫和炎症上调、HLA家族基因转录降低及中性粒细胞活化和炎症。包含一组基因的logistic回归模型可可靠预测临床结局(特异性88%,命中率83%)。
要点
- 院外心脏骤停后昏迷幸存者入院第0天血液中76个转录本在神经预后不良(CPC>2)与良好(CPC 1-2)患者间存在差异,该特征持续至第1天。
- 预后不良组表现为适应性免疫下调、固有免疫和炎症上调、HLA家族基因转录降低及中性粒细胞活化和炎症。
- 包含一组基因的logistic回归模型预测60天神经结局的特异性为88%,命中率为83%。
- EPO治疗未影响心脏骤停后第0天和第1天的转录组反应,两组分别有33例和36例接受或不接受EPO治疗,两组中42%患者神经预后良好。
- 作者认为该转录组特征能在入院后很早期预测神经预后,但需在更大规模人群中确认。
适用人群与场景
- 院外心脏骤停后昏迷幸存者,来自临床试验NCT00999583的辅助研究,共纳入69例。
诊断标准与关键阈值
- 神经预后分类:60天脑功能分类(CPC)1-2为神经预后良好,CPC>2为神经预后不良。
研究设计与关键结果
- 研究类型:临床试验NCT00999583的辅助研究,纳入69例院外心脏骤停后昏迷幸存者,其中33例接受EPO治疗、36例未接受EPO治疗,两组中42%患者神经预后良好。
- 血样采集时间:入院时及复苏后1天和3天;基因表达分析平台为Illumina HumanHT-12 V4 BeadChip(>34,000基因)。
- EPO未影响心脏骤停后第0天和第1天的转录组反应。
- 预后不良组与预后良好组在第0天有76个转录本存在差异,该特征持续至第1天。
- 功能富集分析显示预后不良组较预后良好组适应性免疫下调,伴固有免疫和炎症上调;HLA家族许多基因转录降低,同时观察到中性粒细胞活化和炎症。
- 上游调控因子分析显示涉及众多细胞周期和损伤相关因子。
- 包含一组基因的logistic回归模型可可靠预测临床结局:特异性88%,命中率83%。
证据类型、等级与局限
- 局限:作者指出该转录组特征需在更大规模人群中确认(原文:This deserves confirmation in a larger population)。
对床旁实践的改变
- 作者认为,涉及适应性免疫与固有免疫应答平衡的转录组特征能在院外心脏骤停患者入院后很早期预测神经预后,但需在更大规模人群中确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Early prognostication is a major challenge after out-of-hospital cardiac arrest (OHCA).
AIMS: We hypothesized that a genome-wide analysis of blood gene expression could offer new prognostic tools and lines of research.
METHODS: Sixty-nine patients were enrolled from an ancillary study of the clinical trial NCT00999583 that tested the effect of erythropoietin (EPO) after OHCA. Blood samples were collected in comatose survivors of OHCA at hospital admission and 1 and 3 days after resuscitation. Gene expression profiles were analyzed (Illumina HumanHT-12 V4 BeadChip; >34,000 genes). Patients were classified into two categories representing neurological favorable outcome (cerebral performance category [CPC] = 1-2) vs unfavorable outcome (CPC > 2) at Day 60 after OHCA. Differential and functional enrichment analyses were performed to compare transcriptomic profiles between these two categories.
RESULTS: Among the 69 enrolled patients, 33 and 36 patients were treated or not by EPO, respectively. Among them, 42% had a favorable neurological outcome in both groups. EPO did not affect the transcriptomic response at Day-0 and 1 after OHCA. In contrast, 76 transcripts differed at Day-0 between patients with unfavorable vs favorable neurological outcome. This signature persisted at Day-1 after OHCA. Functional enrichment analysis revealed a down-regulation of adaptive immunity with concomitant up-regulation of innate immunity and inflammation in patients with unfavorable vs favorable neurological outcome. The transcription of many genes of the HLA family was decreased in patients with unfavorable vs favorable neurological outcome. Concomitantly, neutrophil activation and inflammation were observed. Up-stream regulators analysis showed the implication of numerous factors involved in cell cycle and damages. A logistic regression including a set of genes allowed a reliable prediction of the clinical outcomes (specificity = 88%; Hit Rate = 83%).
CONCLUSIONS: A transcriptomic signature involving a counterbalance between adaptive and innate immune responses is able to predict neurological outcome very early after hospital admission after OHCA. This deserves confirmation in a larger population.
参考来源
- Tissier R, Hocini H, Tchitchek N, et al. Early blood transcriptomic signature predicts patients' outcome after out-of-hospital cardiac arrest. Resuscitation. 2019. PMID: 30885824. doi:10.1016/j.resuscitation.2019.03.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。